Please try another search
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Name | Age | Since | Title |
---|---|---|---|
Hidenori Arai | - | - | Member of Scientific Advisory Board |
Jeremy D. Walston | - | - | Member of Scientific Advisory Board |
Elena Volpi | - | - | Member of Scientific Advisory Board |
Rock Soffer | 40 | 2020 | Director |
Joe G. N. Garcia | - | - | Member of Scientific Advisory Board |
Neil E. Hare | 52 | 2015 | Director |
Joshua Michael Hare | 60 | 2014 | Co-Founder, Chief Science Officer & Chairman |
Cathy Ross | 56 | 2021 | Independent Director |
Ursula Ungaro | 72 | 2021 | Independent Director |
Douglas W. Losordo | 66 | 2021 | Independent Director |
Khoso Baluch | 66 | 2023 | Independent Director |
Mohamed Wa'el Ahmed Hashad | 62 | 2023 | CEO & Director |
Richard N. Kender | 68 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review